According to Zacks, “Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company’s product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Entasis Therapeutics Holdings, Inc. is based in Waltham, Massachusetts. “
Several other research firms also recently commented on ETTX. HC Wainwright started coverage on Entasis Therapeutics in a research note on Monday, August 19th. They issued a buy rating and a $18.00 price objective on the stock. ValuEngine raised Entasis Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $16.75.
Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.44). On average, research analysts anticipate that Entasis Therapeutics will post -4.03 EPS for the current fiscal year.
An institutional investor recently raised its position in Entasis Therapeutics stock. BlackRock Inc. boosted its holdings in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) by 29.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,657 shares of the company’s stock after purchasing an additional 3,784 shares during the quarter. BlackRock Inc. owned about 0.13% of Entasis Therapeutics worth $108,000 at the end of the most recent quarter. 64.99% of the stock is currently owned by institutional investors.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Read More: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.